Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Core Viewpoint - Scilex Holding Company has extended the maturity date of its Senior Secured Promissory Note with Oramed Pharmaceuticals, providing additional covenants to support its business operations and future growth in non-opioid pain management products and potential joint ventures [1] Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as treatments for neurodegenerative and cardiometabolic diseases through a proposed joint venture with IPMC Company [1][3] - The company aims to address high unmet needs in the market with non-opioid therapies, enhancing patient outcomes [3] Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved for neuropathic pain relief [3] - ELYXYB, an FDA-approved oral solution for acute migraine treatment [3] - Gloperba, the first liquid oral version of colchicine for gout flare prophylaxis [3] - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections targeting lumbosacral radicular pain, with Phase 3 study completed [4] - SP-103, a next-generation lidocaine topical system for acute pain, recently completed Phase 2 trial [4] - SP-104, a low-dose naltrexone for fibromyalgia treatment [4] Financial and Strategic Developments - The maturity extension of the Oramed Note from March 21, 2025, to December 31, 2025, is aimed at providing the company with more flexibility in its financial obligations [1] - The agreement includes additional covenants that will guide the conduct of the company's business [1]